Fig. 2: ZFP82 enhances esophageal carcinoma chemo-sensitivity in both WTp53 and mutp53 expressing cell lines.
A 3-D cell morphology changes in 5-FU resistance esophageal cells line KYSE960R (WTp53), TE6R (mutp53R248Q) by cell 3-dementional culture (left). Cell viability was measured using the standard MTS assay (right). B MTS assay for cell proliferation on vector and resistance cell lines. The IC50 values for resistance cells were 38.97 vs 25.31 µg/mL in KYSE960/R cells and 46.35 vs 35.67 µg/mL in TE6/R cells. Asterisks indicate a significant level of proliferation compared with vector cells (**, p < 0.01; ***, p < 0.001). C Western blot indicated DNA-PKcs and phosphorylated PI3K were increased in resistance-cell lines KYSE960/R (WTp53), TE6/R (mutp53R248Q). D MTS assay for ectopic expression of ZFP82 and empty vector in drug-resistant cells, The IC50 values for Vector vs ZFP82 were 36.54 vs 10.73 µg/mL in KYSE960/R cells and 45.82 vs 18.89 µg/mL in TE6/R cells (**, p < 0.01; ***: p < 0.001). E Western blot showed in KYSE960 and KYSE960/R, ZFP82 induced cleaved caspase 3, caspase 3, 5 expressions, promoted the acetylation of p53 and induced the expression of BAX (left). In TE6 and TE6/R, ZFP82 has been demonstrated to upregulate the expression of cleaved caspase 3, while concurrently downregulating the expression of mutp53 (right). F Flow cytometry indicated that ZFP82 promotes apoptosis in KYSE960/R and TE6/R. A columnar statistical chart (***: p < 0.001) plotted based on the results of cytology. G Ectopic expression of ZFP82 blocks cell at G0-G1 phase in the presents of chemo-reagent 5-FU in both KYSE960/R and TE6/R (**, p < 0.01).
